Multicomponent synthesis and anticonvulsant activity of monocyclic 2,6-diketopiperazine derivatives

Maciej Dawidowski · Jadwiga Turło

Received: 8 May 2013 / Accepted: 19 September 2013 / Published online: 1 October 2013 © The Author(s) 2013. This article is published with open access at Springerlink.com

Abstract In this study, a series of diastereomerically pure monocyclic 2,6-diketopiperazine (2,6-DKP) derivatives were synthesized. The key synthetic step involved a multicomponent Ugi five-center, four-component reaction which was used to generate the convertible tert-butyldiamidoesters with both good yields and high diastereoselectivity toward the desired bioactive (S,S) absolute configuration. In subsequent steps, selective tert-butyl cleavage by use of BF₃·C₂H₅COOH and base-induced intramolecular cyclocondensation gave the final 2,6-DKP derivatives. The relative stereochemistry of the target molecules was confirmed by ¹H NMR experiments. The compounds obtained were submitted to in vivo screening in animal models of epilepsy. Some of them displayed good activity in maximal electroshock seizure and 6 Hz tests.

Keywords Multicomponent reactions · Ugi reaction · Anticonvulsant activity · 2,6-Diketopiperazine · 2,6-Piperazinedione

Introduction

Epilepsy is a major neurological disorder characterized by recurrent, spontaneous seizures. It affects approx. 50 million people (~1 % of the world’s population). Currently, the main treatment for epilepsy is the chronic administration of anticonvulsant drugs (AEDs). Although more than 30 AEDs are available, they provide satisfactory seizure control in only 60 % of patients. Additionally, major concerns of pharmacotherapy of epilepsy include high incidence of severe side effects and drug–drug interactions resulting from enzyme induction. Therefore, there is substantial need for new, more effective and safer AEDs (Kwan and Brodie, 2000; Brodie, 2001). Another essential challenge for epilepsy research is to develop therapeutics that would not only symptomatically suppress seizures, but would also inhibit or reverse progression of the sickness (the so-called “disease modifying” drugs; Perucca et al., 2007; Bialer and White, 2010).

Presently, the compounds at different stages of development belong to various chemical classes and display diverse, often unknown mechanisms of action (Bialer et al., 2013). Most of these agents have been identified initially through in vivo screening in animal models of epilepsy rather than by a mechanistic approach. Although the animal models utilized for screening are associated with certain endpoints, it is generally accepted that they offer a good starting point in the early discovery of new AED candidates (Löschner and Schmidt, 1994; Malawaska, 2005; Rogawski, 2006; Smith et al., 2007; Bialer and White, 2010; Banerjee and Sharma, 2012; Mishra and Ganguly, 2012).

Recently, we have reported that chiral, bicyclic 2,6-diketopiperazines (2,6-DKPs) derived from cyclic amino acids display a broad anticonvulsant activity in various animal models of epilepsy (Dawidowski et al., 2011, 2012a). Among the newly developed agents, compound ADD408003 exhibited a broad spectrum of seizure-suppressing activity. A preliminary structure–activity relationship (SAR) study of close analogs revealed that several factors are responsible for the anticonvulsant activity (Fig. 1): the (S,S) absolute configuration on the stereogenic centers, the presence of imide moiety and the benzene ring adjacent to 2,6-DKP core. Further, neither substitution of...
the imide nitrogen of ADD408003 with different alkyl and aryalkyl moieties nor expansion of the fused pyrrole chain markedly influenced the antiseizure activity.

These findings led us to ask whether the related monocyclic 2,6-DKPs, derived from non-polar l-amino acids other than l-proline or l-homoproline display comparable anticonvulsant activity. The designed compounds fulfill all requirements determined on the basis of the preliminary SAR analysis, i.e., proper stereochemistry, the presence of imide moiety and benzene ring attached to 2,6-DKP scaffold. Further, due to the absence of the fused pyrrolidine or piperidine rings, these agents are less sterically constrained, which might allow for a better fit to the putative receptor(s).

Results and discussion

Chemistry

The target enantiopure, monocyclic 2,6-DKP derivatives 3a–e were synthesized according to the reaction sequences depicted in Scheme 1.

In the first step, the Ugi five-center four-component reaction (U-5C-4CR; Demharter et al., 1996) of the appropriate non-polar amino acid (l-valine, l-leucine, l-isoleucine, l-phenylalanine, l-phenylglycine), benzaldehyde, tert-butyl isocyanide, and methanol in the presence of a catalytic amount of iron(III) chloride gave the tert-butylamidoesters 1a–e with chemical yields ranging from...
41 to 75 %. The reaction proceeded with the formation of the new stereocenter and in all cases, the major diastereomer was (2S,1S)-1, as judged by the $^1$H NMR analyses of the crude post-reaction mixtures. In general, the degree of diastereoinindunction depended on the steric bulkiness of the side chain of the substrate amino acid. The highest diastereomeric ratios were measured for L-valine and L-isoleucine derivatives 1a ($d_\tau = 7.3/1$) and 1c ($d_\tau = 9.0/1$), respectively, bearing branched alkyl chains directly adjacent to the position C-2, located close to the newly formed stereocenter. The U-5C-4CR adducts of L-leucine and L-phenylalanine 1b and d, respectively, were formed with a slightly lower diastereoiduction ($d_\tau \approx 5/1$ for each). This could be attributed to the lower steric hindrance of a methylene group adjacent to the carbon C-2. A surprisingly small degree of diastereoselectivity was found for the L-phenylglycine derivative 1e ($d_\tau = 1.5/1$), having a bulky phenyl substituent in the position C-2. The possible explanation for this unexpected observation is the stabilization of the six-membered cyclic Ugi intermediate (Demhardt et al., 1996) leading to (2S,1R)-1e by a π–π interaction of the two phenyl rings occupying axial positions.

Attempts to quantitatively separate the diastereoisomers of 1a–e by column chromatography or fractional recrystallization failed. Therefore, the obtained diastereomeric mixtures were used in the subsequent amide N-deuterobutylation. Reaction of (2S,1S)/(2S,1R)-1a–e with BF$_3$CH$_2$COOH at 45–55 °C provided amidoesters 2a–e with the yields range from 55 to 83 %. With the exception of 2e, all diastereomeric mixtures could be efficiently resolved by column chromatography.

In the last step, compounds (2S,1S)-2a–d were subjected to base-induced intramolecular cyclization. The reaction was accompanied by a notable degree of epimerization at stereogenic centers C-5 of the products 3. Nevertheless, in all cases, the unwanted (3S,5R) isomers could be separated by means of column chromatography (compounds (3S,5R)-3a, c, d) or recrystallization (compound (3S,5R)-3b). Intramolecular cyclization of 1.4/1 diastereomeric mixture of (2S,1S)/(2S,1R)-2e gave (3S,5S)-3e and (3S,5R)-3e (a meso compound) in equal proportion. The isomers were efficiently separated by column chromatography.

Relative stereochemistry of the respective diastereoisomers of 2,6-DKPs 3 was confirmed with nuclear Overhauser effect (nOe) $^1$H NMR experiments (Fig. 2) performed for (3S,5S) and (3S,5R)-3a. Contrary to (3S,5R)-3a, the interatomic distance between protons H-3 and H-5 in (3S,5S)-3a should exclude any considerable nOe effect. Indeed, the irradiation of the H-3 resonance in (3S,5R)-3a resulted in a remarkable enhancement of the H-5 signal (4.2 %), whereas no increase in intensity for the proton H-5 was observed in the analogous experiment performed for (3S,5S)-3a. The reverse order of irradiation, consisting in saturation of H-5, led to the enhancement of H-3 resonance in (35S,5R)-3a (4.0 %), but not in (3S,5S)-3a.

The difference in the chemical shifts of the protons H-3 and H-5 adjacent to the stereogenic carbon atoms was another $^1$H NMR spectroscopic feature useful for distinguishing between the respective diastereoisomers of 3. With the exception of 3e, the signals corresponding to H-5 in (3S,5S)-3 were shifted downfield ($\Delta \delta = 0.26–0.38$ ppm [parts per million]) compared to those of (3S,5R)-3. This observation was in agreement with the pseudoaxial arrangement of these protons with respect to the 2,6-DKP ring in (3S,5S)-3, and their pseudoaxial position in (3S,5R)-3. On the contrary, resonances of the H-3 protons in all (3S,5S)-3 isomers were shifted upfield ($\Delta \delta = 0.14–0.32$ ppm). Although these protons in both respective diastereoisomers occupy the same pseudoaxial positions, the slightly stronger shielding in (3S,5R)-3 could be attributed to the anisotropic effect of the phenyl ring present in the spatial vicinity.

The racemic 2,6-DKPs 3f, g were synthesized from the corresponding N-substituted glycines in a similar manner, according to the reaction sequences depicted in Scheme 2. Notably, the chemical yields of racemic U-5C-4CR products 1f and g (18 and 24 %, respectively) were significantly lower than those observed for N-unsubstituted adducts 1a–e.

Anticonvulsant screening

Compounds 3a–f were evaluated in the in vivo animal models of epilepsy within the Anticonvulsant Screening Program (ASP) of The National Institute of Neurological Disorders and Stroke (NINDS), at The National Institutes of Health according to well-established protocols described in the “Experimental” section of this article. The compounds were screened using maximal electroshock seizure (MES) and subcutaneous metrazole (scMET) tests (White et al., 2002). The first of these tests uses an electrical stimulus to induce generalized tonic–clonic seizures and is capable of identifying compounds that prevent the spread of seizure. The latter employs chemically induced seizures to recognize agents that raise the seizure threshold. The most promising compounds were subjected to an evaluation of anticonvulsant activity using a minimal clonic seizure (6 Hz) test (Brown et al., 1953; Barton et al., 2001; Kaminski et al., 2004), which is regarded as a preliminary model of pharmacoresistant limbic seizures. Additionally, a standardized rotorod test for neurological toxicity (TOX; Dunham and Miya, 1957) was performed for each compound. The results are summarized in Tables 1 and 2.

As shown in Table 1, compounds 3a, b, d–f exhibited weak to good anticonvulsant activities in the MES model in mice. (3S,5S)-3a and (3S,5S)-3e were most potent, displaying a notable seizure protection in 2/3 and 2/4 of tested
animals, respectively, at the dose of 100 mg/kg, after 0.5 h postadministration. No neurotoxicity was detected at the same dose. (3S,5S)-3e also proved effective also at the later time points (1/4 and 4/4 at 100 and 300 mg/kg, respectively, at 2.0 h). None of the compounds investigated were significantly active in the scMET model.

According to our previous reports on bicyclic 2,6-DKP derivatives, the (R,S) isomers were completely devoid of any in vivo pharmacological activity (Dawidowski et al., 2011, 2012a). In contrast, the monocyclic derivatives (3R,5S)-3a and (3S,5S)-3e, displayed a weak, yet noticeable activity in the MES test (1/1 and 1/4 at 300 mg, respectively, at 0.5 h). This could mean that the greater flexibility due to the lack of fused alkyl rings allows for a better fit in the putative binding site within the CNS. Nevertheless, the (S,S) isomers again proved more active.

In general, the most significant levels of seizure protection were observed for derivatives bearing alkyl or aryl substituents at carbon C-5. Among the compounds with alkyl groups, the t-valine derivative with isopropyl side chain (3S,5S)-3a was most potent in the MES test. High levels of seizure protection was also observed for symmetrical (3S,5S)-3e having two benzene rings with a proper stereochemistry with respect to the 2,6-DKP core. Importantly, the anticonvulsant activity of the investigated molecules was not dependant on their logP values.

Derivatives (3S,5S)-3a and (3S,5S)-3e were further assessed for their potential efficacy against pharmacoresistant epilepsy using the 6 Hz screen. The results are summarized in Table 2. Notable activity was detected for the first compound (2/4 and 1/4, at 0.25 and 0.5 h, respectively, at 100 mg/kg), while the latter was inactive.

**Conclusions**

We have synthesized a series of novel diastereomerically pure, monocyclic 2,6-DKP derivatives by use of diastereoselective synthetic sequence using the U-5C-4CR multicomponent reaction as the key step. The compounds displayed weak to good anticonvulsant activities in the MES model, while none of them were active in scMET screen. The most promising compound (3S,5S)-3a exhibited notable action in the 6 Hz test. Contrary to the recently reported activity of bicyclic 2,6-DKP, the activity of monocyclic derivatives seemed to be less stereochemistry-dependent. We conclude that this is due to increased conformational flexibility. Although the seizure-suppressing potency of the newly synthesized agents was generally weaker relative to bicyclic 2,6-DKPs, they possess secondary amino groups that provide additional points of diversification for further SAR studies.

**Experimental**

Chemistry

Melting points were determined on an Electrothermal 9100 apparatus in open capillary tubes and were uncorrected. The IR spectra (thin film on KBr pellets) were recorded on a Shimadzu FTIR-8300 instrument. The NMR spectra were obtained on a Varian Inova 500 MHz spectrometer. Chemical shifts (δ) were expressed in ppm relative to tetramethylsilane or solvent used as the internal reference. The following abbreviations were used to describe the peak patterns: s (singlet), d (doublet), t (triplet), q (quartet), qt (quintet), sp (septet), m (multiplet), p (pseudo-), and b
Table 1 Anticonvulsant activity and neurotoxicity of compounds in the MES and scMET models following intraperitoneal (ip) administration in mice

| Compounds | Dose (mg/kg) | MESa 0.5 h | scMETb 0.5 h | MESa 4.0 h | scMETb 4.0 h | TOXc | CLogPd |
|-----------|-------------|------------|--------------|------------|--------------|-------|-------|
| (3S,5S)-3a | 30 | 0/1 | 0/1 | 0/1 | 0/1 | 0/4 | 0/2 | 0.80 |
|           | 100 | 2/3 | 0/3 | 0/1 | 0/1 | 0/8 | 0/4 |       |
|           | 300 | 1/1 | 0/1 | 0/1 | 0/1 | 4/4 | 0/2 |       |
| (3S,5S)-3a | 30 | 0/1 | 0/1 | 0/1 | 0/1 | 0/4 | 0/2 | 0.80 |
|           | 100 | 0/3 | 0/3 | 0/1 | 0/1 | 0/8 | 0/4 |       |
|           | 300 | 1/1 | 0/1 | 0/1 | 0/1 | 2/4 | 0/2 |       |
| (3S,5S)-3b | 30 | 0/1 | 0/1 | 0/1 | 0/1 | 0/4 | 0/2 | 1.19 |
|           | 100 | 0/3 | 0/3 | 0/1 | 0/1 | 0/8 | 0/4 |       |
|           | 300 | 1/1 | 0/1 | 0/1 | 0/1 | 3/4 | 0/2 |       |
| (3S,5S)-3c | 30 | 0/1 | 0/1 | 0/1 | 0/1 | 0/4 | 0/2 | 1.19 |
|           | 100 | 0/3 | 0/3 | 0/1 | 0/1 | 0/8 | 0/4 |       |
|           | 300 | 0/1 | 0/1 | 0/1 | 0/1 | 2/4 | 0/2 |       |
| (3S,5S)-3d | 30 | 0/1 | 0/1 | 0/1 | 0/1 | 0/4 | 0/2 | 1.61 |
|           | 100 | 0/3 | 0/3 | 0/1 | 0/1 | 0/8 | 0/4 |       |
|           | 300 | 0/1 | 0/1 | 0/1 | 0/1 | 2/4 | 0/2 |       |
| (3S,5S)-3e | 30 | 0/4 | 0/4 | – | – | 0/8 | 0/8 | 2.12 |
|           | 100 | 2/4 | 1/4 | – | – | 0/8 | 0/8 |       |
|           | 300 | 4/4 | 4/4 | – | – | 2/8 | 1/8 |       |
| (3S,5R)-3e | 30 | 0/4 | 0/4 | – | – | 0/8 | 0/8 | 2.12 |
|           | 100 | 0/4 | 0/4 | – | – | 0/8 | 0/8 |       |
|           | 300 | 1/4 | 0/4 | – | – | 0/8 | 0/8 |       |
| rac-3f    | 30 | 0/4 | 0/4 | – | – | 0/8 | 0/8 | 2.29 |
|           | 100 | 0/4 | 0/4 | – | – | 0/8 | 0/8 |       |
|           | 300 | 0/4 | 3/4 | – | – | 0/8 | 0/8 |       |
| rac-3g    | 30 | 0/1 | 0/1 | 0/1 | 0/1 | 0/4 | 0/2 | 2.12 |
|           | 100 | 0/3 | 0/3 | 0/1 | 0/1 | 0/8 | 0/4 |       |
|           | 300 | 0/1 | 0/1 | 0/1 | 0/1 | 0/4 | 0/2 |       |

Ratios where at least one animal was protected or displayed neurotoxicity have been highlighted in bold to enhance data readability and interpretation

a Maximal electroshock test (number of animals protected/number of animals tested)
b Subcutaneous metrazole test (number of animals protected/number of animals tested)
c Neurotoxicity test (number of animals exhibiting neurological toxicity/number of animals tested)
d Theoretical logP value calculated by a logarithm included in HyperChem 7.5 package

e Compounds (3S,5S)-3e, (3S,5R)-3e and rac-3f were tested at 2.0 h post administration
f Unable to grasp rotorod
g Loss of righting reflex
h Active also in 1/3 at 0.25 h post administration
i Myoclonic jerks

Table 2 Anticonvulsant activity and neurotoxicity of compounds in the 6 Hz model following intraperitoneal (ip) administration in mice

| Compounds | Testa | 0.25 h | 0.5 h | 0.5 h | 1.0 h | 1.0 h | 2.0 h | 2.0 h | 4.0 h |
|-----------|-------|--------|--------|--------|--------|--------|--------|--------|--------|
| (3S,5S)-3a | 6 Hzb | 2/4 | 1/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 |
| TOXc | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 |       |
| (3S,5S)-3e | 6 Hz | – | 0/4 | – | 0/4 | – | 0/4 | – | – |
| TOX | – | 0/8 | – | 0/8 | – | 0/8 | – | – |

Ratios where at least one animal was protected or displayed neurotoxicity have been highlighted in bold to enhance data readability and interpretation

a At dose 100 mg/kg
b 6 Hz test, 32 mA (number of animals protected/number of animals tested)
c Neurotoxicity test (number of animals exhibiting neurological toxicity/number of animals tested)

Synthesis of compounds 1 by U-5C-4CR condensation

Iron(III) chloride (5 mol.%) and tert-butyl isocyanide (1.0 equiv.) were added to a stirred suspension of appropriate α-amino acid (1.2 equiv.) and benzaldehyde (1.0 equiv.) in MeOH (100 mL). The mixture was stirred at RT for 48 h and the volatiles were removed under reduced pressure. The resulting crude products were purified FC.

Methyl (2S,1S)- and (2S,1R)-2-(2-(tert-butylationo)-2-oxo-1-phenylethylamino)-3-methylbutanoate (2S,1S)-1a and (2S,1R)-1a

From l-valine (2.36 g, 20.16 mmol), benzaldehyde (16.80 mmol, 1.71 mL) and tert-butyl isocyanide (2.00 mL, 16.80 mmol); FC (gradient: PE/AcOEt 6:1–3:1): yield 4.04 g (75%) of chromatographically inseparable...
diastereomeric mixture ($d = 7.3/1$, $^1$H NMR). Analytical sample of (2S,1S)-1a was obtained by recrystallization from PE/EtO 10:1. (2S,1S)-1a: white wax; mp 37–38 °C; [α]D = −97.2 (c 1, CHCl3); IR (KBr): 729, 764, 1200, 1454, 1516, 1678, 1736, 2874, 2962, 3333; TLC (PE/AcOEt 3:1): $R_f = 0.43$; $^1$H NMR (CDCl3, 500 MHz): $\delta$ 0.89 (d, $^3J = 6.5$, 3H, $CH_3$), 0.93 (d, $^3J = 6.5$, 3H, $CH_3$), 1.29 (s, 9H, C(CH$_3$)$_3$), 1.96 (m, $^3J = 6.5$, 1H, CH$_2$), 2.34 (bs, 1H, NH), 2.87 (bpd, $^3J = 5.0$, 1H, H-2), 3.71 (s, 3H, OCH$_3$), 4.08 (s, 1H, H-1), 6.37 (bs, 1H, CONH). 7.28–7.36 (m, 5H, H–Ar); $^1$C NMR (CDCl3, 125 MHz): $\delta$ 18.0 (CH$_3$), 19.6 (CH$_3$), 28.8 (C(CH$_3$)$_3$), 31.5 (CH), 50.7 (C(CH$_3$)$_3$), 51.8 (OCH$_3$), 66.3 (C-1), 67.0 (C-2), 127.2 (C-2', C-6'), 128.3 (C-4'), 128.8 (C-3', C-5'), 139.6 (C-1'), 170.9 (CONH), 175.0 (COOCH$_3$).

Methyl (2S,1S)- and (2S,1R)-2-(2-(tert-butylamino)-2-oxo-1-phenylethylamino)-4-methylpentanoate (2S,1S,3S)-1c and (2S,1R,3S)-1c

From l-isoleucine (2.64 g, 20.16 mmol), benzaldehyde (16.80 mmol, 1.71 mL) and tert-butyl isocyanide (2.00 mL, 16.80 mmol); FC (gradient: PE/AcOEt 9:1–4:1): yield 3.97 g (71 %) of chromatographically inseparable diastereomeric mixture ($d = 9.0/1$, $^1$H NMR). Colorless oil; IR (KBr): 700, 741, 1148, 1200, 1225, 1265, 1454, 1516, 1678, 1736, 2876, 2930, 2964, 3329; TLC (PE/AcOEt 3:1): $R_f = 0.35$; $^1$H NMR (from diastereomeric mixture, CDCl$_3$, 500 MHz): (2S,1S,3S)-1c (major isomer): $\delta$ 0.85 (t, $^3J = 7.5$, 3H, CH$_2$CH$_3$), 0.85 (d, $^3J = 7.0$, 3H, CH$_3$), 1.16 (m, 1H, CH$_2$), 1.30 (s, 9H, C(CH$_3$)$_3$), 1.51 (m, 1H, CH$_2$), 1.72 (m, 1H, CH$_3$), 2.35 (bs, 1H, NH), 2.94 (d, $^3J = 6.0$, 1H, H-2), 3.71 (s, 3H, OCH$_3$), 4.07 (s, 1H, H-1), 6.37 (bs, 1H, CONH), 7.27–7.34 (m, 5H, H–Ar); (2S,1R,3S)-1c (minor isomer): $\delta$ 0.92 (t, $^3J = 7.5$, 3H, CH$_2$CH$_3$), 1.00 (d, $^3J = 7.0$, 3H, CH$_3$), 1.39 (s, 9H, C(CH$_3$)$_3$), 3.17 (d, $^3J = 5.5$, 1H, H-2), 3.72 (s, 3H, OCH$_3$), 3.93 (s, 1H, H-1), 5.30 (bs, 1H, CONH), the remaining signals overlap with the signals of (2S,1S,3S)-1c; $^1$C NMR (from diastereomeric mixture, CDCl$_3$, 125 MHz): (2S,1S,3S)-1c (major isomer): $\delta$ 11.3, 15.6 (CH$_3$), 25.3 (CH$_2$), 28.6 (C(CH$_3$)$_3$), 38.0 (CH), 50.9 (C(CH$_3$)$_3$), 51.5 (OCH$_3$), 63.5 (C-2), 66.6 (C-1), 127.9 (C-2', C-6'), 128.2 (C-4'), 128.8 (C-3', C-5'), 138.8 (C-1'), 170.9 (CONH), 174.7 (COOCH$_3$); HRMS (ESI) calead for C$_{18}$H$_{28}$N$_2$O$_3$Na: 357.2154 (M+Na)$^+$ found 357.2171.

Methyl (2S,1S,3S)- and (2S,1R,3S)-2-(2-(tert-butylamino)-2-oxo-1-phenylethylamino)-3-methylpentanoate (2S,1S,3S)-1d and (2S,1R,3S)-1d

From l-phenylalanine (3.33 g, 20.16 mmol), benzaldehyde (16.80 mmol, 1.71 mL) and tert-butyl isocyanide (2.00 mL, 16.80 mmol); FC (gradient: PE/AcOEt 9:1–4:1): yield 3.23 g (52 %) of diastereomeric mixture ($d = 5.1/1$, $^1$H NMR). Pale-yellow oil; IR (KBr): 700, 754, 1223, 1454,
From α-phenylglycine (3.05 g, 20.16 mmol), benzaldehyde (16.80 mmol, 1.71 mL) and tert-butyl isocyanide (2.00 mL, 16.80 mmol); FC (gradient: PE/AcOEt 5:1–1:2); yield 2.41 g (41 %) of chromatographically inseparable diastereomeric mixture (d, 1.5/1, 1H NMR). Pale-yellow wax; mp 65–71 °C; IR (KBr): 700, 733, 1223, 1454, 1516, 1678, 1740, 2872, 2930, 2966, 3333; TLC (PE/AcOEt 3:1); Rf = 0.28; 1H NMR (from diastereomeric mixture, CDCl3, 500 MHz): (2S,1S)-1e (major isomer): δ 1.35 (s, 9H, C(CH3)3), 2.85 (bs, 1H, NH), 3.69 (s, 3H, OCH3), 3.99 (s, 1H, H-1), 4.33 (s, 1H, H-2), 6.88 (bs, 1H, CONH), 7.23–7.38 (m, 10H, H–Ar); (2S,1R)-1e (minor isomer): δ 1.27 (s, 9H, C(CH3)3), 2.78 (bs, 1H, NH), 3.69 (s, 3H, OCH3), 4.05 (s, 1H, H-1), 4.29 (s, 1H, H-2), 6.97 (bs, 1H, CONH); the remaining signals overlap with the signals of (2S,1S)-1e.

Methyl (2S,1S)- and (2S,1R)-2-(2-tert-butylamino)-2-oxo-1-phenylethylamino)-3-methylbutanoate (2S,1S)-2a and (2S,1R)-2a

From diastereomeric mixture of (2S,1S)-1a and (2S,1R)-1a (3.98 g, 12.43 mmol) and BF3·2CH3COOH (37 mL); FC (gradient: PE/AcOEt 2:1–0:1); yield 2.31 g (70 %): 1.95 g (C(CH3)3), 50.7 (C(CH3)3), 52.4 (OCH3), 64.1 (C-2), 66.9 (C-1), 127.3, 127.5 (C-2′, C-6′, C-2″, C-6″), 128.2, 128.4 (C-4′, C-4″), 128.9, 129.0 (C-3′, C-5′, C-3″, C-5″), 137.9, 139.0 (C-1′, C-1″), 170.6 (CONH), 172.6 (COOCH3); (2S,1S)-1e (minor isomer): δ 28.6 (C(CH3)3), 50.7 (C(CH3)3), 52.4 (OCH3), 64.1 (C-2), 66.9 (C-1), 127.3, 127.5 (C-2′, C-6′, C-2″, C-6″), 128.2, 128.4 (C-4′, C-4″), 128.9, 129.0 (C-3′, C-5′, C-3″, C-5″), 137.9, 139.0 (C-1′, C-1″), 170.6 (CONH), 172.6 (COOCH3);
(59%) of (2S,1S)-2a, 0.19 g (6%) of (2S,1R)-2a and 0.17 g (5%) of diastereomeric mixture. 

Methyl (2S,1R,3S)- and (2S,1S,3S)-2-(2-amino-2-oxo-1-phenylethylamino)-3-methylpentanoate (2S,1S,3S)-2c

From diastereomeric mixture of (2S,1S)-2b and (2S,1R)-2b (3.11 g, 9.31 mmol) and BF₃·OCH₃ (35 mL); FC (gradient: PE/AcOEt 2:1–0:1): yield 1.43 g (55%); 1.03 g (40%) of (2S,1S)-2b, 0.08 g (3%) of (2S,1R)-2b and 0.32 g (12%) of diastereomeric mixture.

From diastereomeric mixture of (2S,1S)-2b and (2S,1R)-2b (3.11 g, 9.31 mmol) and BF₃·OCH₃ (35 mL); FC (gradient: PE/AcOEt 2:1–0:1): yield 1.43 g (55%); 1.03 g (40%) of (2S,1S)-2b, 0.08 g (3%) of (2S,1R)-2b and 0.32 g (12%) of diastereomeric mixture.

From diastereomeric mixture of (2S,1S)-1c and (2S,1R)-1c (4.14 g, 25.1 mmol) and BF₃·OCH₃ (35 mL); FC (gradient: PE/AcOEt 2:1–0:1): yield 1.31 g (40%); 0.91 g (28%) of (2S,1S,3S)-2c and 0.78 g (24%) of diastereomeric mixture.

Methyl (2S,1R,3S)- and (2S,1S,3S)-2-(2-amino-2-oxo-1-phenylethylamino)-3-methylpentanoate (2S,1S,3S)-2c

From diastereomeric mixture of (2S,1S,3S)-1c and (2S,1R,3S)-1c (3.96 g, 11.85 mmol) and BF₃·OCH₃ (35 mL); FC (gradient: PE/AcOEt 2:1–0:1): yield 2.75 g (83%); 1.92 g (58%) of (2S,1S,3S)-2c, 0.05 g (1%) of (2S,1R,3S)-1c and 0.78 g (24%) of diastereomeric mixture.

Methyl (2S,1R,3S)- and (2S,1S,3S)-2-(2-amino-2-oxo-1-phenylethylamino)-3-methylpentanoate (2S,1S,3S)-2c

From diastereomeric mixture of (2S,1S,3S)-1c and (2S,1R,3S)-1c (3.96 g, 11.85 mmol) and BF₃·OCH₃ (35 mL); FC (gradient: PE/AcOEt 2:1–0:1): yield 2.75 g (83%); 1.92 g (58%) of (2S,1S,3S)-2c, 0.05 g (1%) of (2S,1R,3S)-1c and 0.78 g (24%) of diastereomeric mixture.

Methyl (2S,1R,3S)- and (2S,1S,3S)-2-(2-amino-2-oxo-1-phenylethylamino)-3-methylpentanoate (2S,1S,3S)-2c

From diastereomeric mixture of (2S,1S,3S)-1c and (2S,1R,3S)-1c (3.96 g, 11.85 mmol) and BF₃·OCH₃ (35 mL); FC (gradient: PE/AcOEt 2:1–0:1): yield 2.75 g (83%); 1.92 g (58%) of (2S,1S,3S)-2c, 0.05 g (1%) of (2S,1R,3S)-1c and 0.78 g (24%) of diastereomeric mixture.

From diastereomeric mixture of (2S,1S,3S)-1c and (2S,1R,3S)-1c (3.96 g, 11.85 mmol) and BF₃·OCH₃ (35 mL); FC (gradient: PE/AcOEt 2:1–0:1): yield 2.75 g (83%); 1.92 g (58%) of (2S,1S,3S)-2c, 0.05 g (1%) of (2S,1R,3S)-1c and 0.78 g (24%) of diastereomeric mixture.
Methyl (2S,1R)- and (2S,1S)-2-(2-amino-2-oxo-1-phenylethylamino)-3-phenylpropanoate (2S,1R)-2d and (2S,1S)-2d

From diastereomeric mixture of (2S,1S)-1d and (2S,1R)-1d (2.34 g, 6.36 mmol) and BF₃·C₂H₅COOH (19 mL); FC (gradient: PE/AcOEt 2:1–0:1); yield 1.32 g (67 %): 1.10 g (55 %) of (2S,1S)-2d and 0.22 g (12 %) of (2S,1R)-2d. (2S,1S)-2d: pale-yellow oil; [α]D = –72.3 (c 0.392, CHCl₃); IR (KBr): 702, 752, 1205, 1454, 1682, 1734, 2854, 2951, 3028, 3190, 3325, 3445; TLC (AcOEt): Rₜ = 0.46; ¹H NMR (CDCl₃, 500 MHz): δ 2.40 (bs, 1H, NH), 2.85 (dd, ³J = 13.5, ³J = 8.0, 1H, CH₂), 3.03 (dd, ²J = 13.5, ³J = 6.0, 1H, CH₂), 3.38 (bs, ³J = 6.0, 1H, H–Ar), 3.67 (s, 3H, OCH₃), 4.22 (s, 1H, H–1), 5.60 (bs, 1H, CONH), 6.44 (bs, 1H, CONH); 7.09 (m, 2H, H–Ar), 7.12 (m, 2H, H–Ar), 7.21–7.30 (m, 6H, H–Ar); ¹³C NMR (CDCl₃, 125 MHz): δ 39.4 (CH₂), 51.9 (OCH₃), 60.1 (C-2), 65.3 (C-1), 126.8 (C-4”), 127.7 (C-2”), 128.3 (C-4”), 128.4 (C-2”, C-6’), 128.8 (C-3’, C-5’), 129.2 (C-3”, C-5”), 136.9 (C-1’), 137.7 (C-1’), 174.1 (COOCH₃), 174.2 (CONH); HRMS (ESI+) calcd for C₁₈H₁₈N₂O₃Na: 335.1372 (M+Na⁺) found 335.1363. (2S,1R)-2d: white powder; mp 124–127 °C; [α]D = –37.8 (c 0.775, CHCl₃); IR (KBr): 702, 739, 1209, 1452, 1693, 1734, 2951, 3030, 3188, 3335, 3429; TLC (AcOEt): Rₜ = 0.58; ¹H NMR (CDCl₃, 500 MHz): δ 2.21 (bs, 1H, NH), 2.68 (dd, ²J = 13.5, ³J = 10.0, 1H, CH₂), 3.11 (dd, ²J = 13.5, ³J = 4.0, 1H, CH₂), 3.47 (bps, ³J = 6.0, 1H, H–2), 3.76 (s, 3H, OCH₃), 4.08 (s, 1H, H–1), 5.04 (bs, 1H, CONH), 6.32 (bs, 1H, CONH); 7.23–7.42 (m, 10H, H–Ar); ¹³C NMR (CDCl₃, 125 MHz): δ 40.1 (CH₂), 52.2 (OCH₃), 62.3 (C-2), 66.4 (C-1), 127.0 (C-4”), 127.3 (C-2”, C-6’), 128.4 (C-4”), 128.6 (C-2”, C-6’), 128.9 (C-3’, C-5’), 129.6 (C-3”, C-5”), 137.7 (C-1’), 138.6 (C-1’), 174.5 (COOCH₃), 174.6 (CONH); C₁₈H₂₀N₂O₃Na: 335.1372 (M+Na⁺) found 335.1366.

Methyl (2S,1S)- and (2S,1R)-2-(2-amino-2-oxo-1-phenylethylamino)-3-phenylacetate (2S,1S)-2e and (2S,1R)-2e

From diastereomeric mixture of (2S,1S)-1e and (2S,1R)-1e (2.26 g, 6.38 mmol) and BF₃·C₂H₅COOH (19 mL); FC (gradient: PE/AcOEt 4:1–1:2); yield 0.40 g (80 %) of (2S,1S)-2e. White powder; mp 147–149 °C; TLC (AcOEt): Rₜ = 0.63; IR (KBr): 700, 741, 1204, 1454, 1558, 1682, 1734, 2844, 2951, 3030, 3182, 3418; ¹H NMR (CDCl₃, 500 MHz): δ 3.07 (d, ²J = 17.5, 1H, PhCH₂), 3.40 (d, ²J = 17.5, 1H, PhCH₂), 3.61 (s, 3H, OCH₃), 3.66 (d, ²J = 13.5, 1H, CH₂), 3.85 (d, ²J = 13.5, 1H, CH₂), 4.75 (s, 1H, H–1), 5.85 (bs, 1H, CONH), 6.72–7.42 (m, 10H, H–Ar), 7.63 (bs, 1H, CONH); ¹³C NMR (CDCl₃, 125 MHz): δ 51.7 (OCH₃), 51.8 (PhCH₂), 56.8 (CH₂), 69.9 (C-1), 127.7, 128.4 (C-4”, C-4”), 128.6, 128.5 (C-2’, C-2”, C-6’), 129.0, 129.6 (C-3’, C-3”, C-5’, C-5”), 134.7, 137.5 (C-1’, C-1”), 172.3 (CONH), 174.4 (COOCH₃); HRMS (ESI+) calcd for C₁₉H₁₈N₂O₃Na: 335.1360 (M+Na⁺) found 335.1372.

Synthesis of compounds 3 by base-induced intramolecular cyclocondensation

To a stirred solution of appropriate amidoester 2 in absolute EtOH (5 mL/1 mmol of amidoester), sodium hydroxide (1 equiv.) was added at room temperature. After dissolution of the hydroxide, the mixture was quenched with saturated aqueous solution of ammonium chloride (100 mL). The resulting cloudy solution was extracted with CH₂Cl₂ (3 × 30 mL). The combined organic phase was washed with water (20 mL), dried over anhydrous MgSO₄, filtered and concentrated under reduced pressure. The residue was purified by FC.

(3S,5R)- and (3S,5S)-3-isopropyl-5-phenylpiperazine-2,6-dione (3S,5S)-3a and (3S,5R)-3a

From (2S,1S)-2a (1.86 g, 7.04 mmol) and NaOH (0.28 g, 1 equiv.); FC (gradient: PE/EtOAc 6:1–1:1); yield 1.34 g
(82%); 0.72 g (44%) of (3S,5S)-3a, 0.32 g (19%) of (3S,5R)-3a and 0.30 g (19%) of diastereomeric mixture. (3S,5S)-3a: white powder; mp 103–105 °C; [ξ]D = −152.1 (c 1, CHCl3); IR (KBr): 756, 1030, 1099, 1180, 1234, 1454, 1497, 1701, 2932, 1963, 3225; TLC (PE/AcOEt 3:1): Rf = 0.35; 1H NMR (CDCl3, 500 MHz): δ 0.99 (d, 3J = 7.0, 3H, CH3), 1.09 (d, 3J = 7.0, 3H, CH3), 2.18 (bs, 1H, NH), 2.49 (2 sp, 3J1 = 6.5, 3J2 = 5.0, 1H, CH3), 3.26 (d, 3J = 4.5, 1H, H-3), 4.90 (s, 1H, H-5), 7.27–7.46 (m, 5H, H–Ar), 8.34 (bs, 1H, CONHCO); 13C NMR (CDCl3, 125 MHz): δ 17.1 (CH3), 19.3 (CH3), 27.7 (CH), 58.2 (C-3), 59.8 (C-5), 127.1 (C-2', C-6'), 128.5 (C-4', 129.0 (C-3', C-5'), 134.6 (C-1'), 172.3 (C-6), 173.1 (C-2); HRMS (ESI+) calcld for C13H16N2O2Na: 255.1109 (M+Na)+ found 255.1129.

(3S,5S)- and (3S,5R)-3-isobutyl-5-phenylpiperazine-2,6-dione (3S,5S)-3b and (3S,5R)-3b

From (2S,1S)-2b (0.92 g, 3.31 mmol) and NaOH (0.13 g, 1 equiv.); FC (gradient: PE/EtOAc 5:1–2:1); yield 0.63 g (77%) of chromatographically inseparable diastereomeric mixture (d = 68/32, 1H NMR). Pure (3S,5S)-3b was obtained by fractional recrystallization form PE/EtO 1:1. (3S,5S)-3b: white powder; mp 60–61 °C; [ξ]D = −30.3 (c 1, CHCl3); IR (KBr): 756, 1242, 1384, 1454, 1701, 2870, 2955, 3090, 3225, 3321; TLC (PE/AcOEt 3:1): Rf = 0.36; 1H NMR (CDCl3, 500 MHz): δ 0.84 (d, 3J = 6.5, 3H, CH3), 0.97 (d, 3J = 6.5, 3H, CH3), 1.57 (m, 2J = 13.5, 3J = 9.5, 3J = 4.0, 1H, CH2), 1.85 (m, 1H, CH), 1.89 (m, 1H, CH), 2.07 (bs, 1H, NH), 3.44 (pd, 3J = 9.5, 1H, H-3), 4.86 (s, 1H, H-5), 7.30–7.47 (m, 5H, H–Ar), 8.34 (bs, 1H, CONHCO); 13C NMR (CDCl3, 125 MHz): δ 21.1 (CH3), 22.3 (CH3), 24.4 (CH), 38.7 (CH2), 52.1 (C-3), 59.7 (C-5), 127.2 (C-2', C-6'), 128.5 (C-4'), 128.9 (C-3', C-5'), 134.7 (C-1'), 172.3 (C-6), 174.3 (C-2); HRMS (ESI+) calcld for C14H16N2O2Na: 269.1266 (M+Na)+ found 269.1280.

(3S,5R)- and (3S,5S)-3-benzyl-5-phenylpiperazine-2,6-dione (3S,5S)-3d and (3S,5R)-3d

From (2S,1S)-2d (1.02 g, 3.27 mmol) and NaOH (0.13 g, 1 equiv.); FC (gradient: PE/EtOAc 6:1–2:1); yield 0.71 g (78%); 0.44 g (48%) of (3S,5S)-3d, 0.27 g (39%) of (3S,5R)-3d. (3S,5S)-3d: white powder; mp 114–115 °C; TLC (PE/AcOEt 3:1): Rf = 0.34; [ξ]D = −88.2 (c 1, CHCl3); IR (KBr): 764, 1261, 1342, 1450, 1497, 1701, 2812, 3028, 3159, 3263, 3287; 1H NMR (CDCl3, 500 MHz): δ 2.12 (bs, 1H, NH), 3.16 (dd, 3J = 14.0, 3J = 8.0, 1H, CH2), 3.25 (dd, 3J = 14.0, 3J = 4.5, 1H,
CH₂), 3.72 (dd, 3J₁ = 8.0, 3J₂ = 4.5, 1H, H-3), 4.82 (s, 1H, H-5), 7.21–7.36 (m, 10H, H-Ar), 8.27 (bs, 1H, CONHCO); ¹³C NMR (CDCl₃, 125 MHz): δ 35.5 (CH₂), 54.7 (C-3), 59.8 (C-5), 127.1 (C-2', C-6'), 127.3 (C-4''), 128.5 (C-4'), 128.9 (C-2'', C-6''), 129.8 (C-3', C-5'), 129.4 (C-3''', C-5'''), 134.4 (C-1'), 136.3 (C-1''), 171.7 (C-6), 172.7 (C-2); HRMS (ESI+) calcld for C₁₇H₁₆N₂O₂Na: 303.1109 (M+Na⁺) found 303.1132; (3S,5R)-3d: white powder; mp 98–99 °C; TLC (PE/AcOEt 3:1): Rf = 0.28; [α]D = -184.2 (c 1, CHCl₃); IR (KBr): 760, 1230, 1288, 1454, 1716, 2851, 3086, 3182; ¹H NMR (CDCl₃, 500 MHz): δ 1.89 (t, 1H, NH), 2.93 (dd, 3J₂ = 14.0, 3J₁ = 9.5, 1H, H-7), 3.62 (dd, 3J₁ = 8.0, 3J₂ = 2.5, 1H, H-7'), 3.86 (dd, 3J₁ = 8.0, 3J₂ = 2.5, 1H, H-3), 4.46 (s, 1H, H-5), 7.22–7.38 (m, 10H, H-Ar), 8.18 (bs, 1H, NH); ¹³C NMR (CDCl₃, 125 MHz): δ 36.5 (CH₂), 60.5 (C-3), 64.5 (C-5), 127.2 (C-4'), 128.5 (C-2', C-6'), 128.7 (C-3', C-5'), 128.8 (C-4'), 129.0 (C-2'', C-6''), 129.3 (C-3'', C-5''), 136.0 (C-1'), 136.7 (C-1''), 171.4 (C-6), 171.8 (C-2); HRMS (ESI+) calcld for C₁₇H₁₆N₂O₂Na: 303.1109 (M+Na⁺) found 303.1115.

(3,5R)- and (3S,5S)-3,5-diphenylpiperazine-2,6-dione (3S,5R)-3e and (3S,5R)-3f

From diastereomeric mixture of (2S,1S)-2e and (2S,1R)-2e (1.43 g, 4.80 mmol) and NaOH (0.19 g, 1 equiv.); FC (gradient: PE/EtOAc 6:1–2:1); yield 0.94 g (74%); 0.52 g (41%) of (3S,5R)-3e, 0.42 g (33%) of (3S,5R)-3f. (3S,5R)-3e: white powder; mp 126–129 °C; TLC (PE/ AcOEt 3:1): Rf = 0.17; [α]D = +5.5 (c 0.887, CHCl₃); IR (KBr): 700, 744, 1240, 1454, 1695, 2855, 2922, 3070, 3204, 3312; ¹H NMR (CDCl₃, 500 MHz): δ 2.48 (bs, 1H, NH), 4.76 (s, 2H, H-3, H-5), 7.36–7.44 (m, 10H, H-Ar), 8.22 (bs, 1H, CONHCO); ¹³C NMR (CDCl₃, 125 MHz): δ 59.5 (C-3, C-5), 127.7 (C-2', C-6', C-2'', C-6''), 128.8 (C-4', C-4''), 129.1 (C-3', C-5', C-3'', C-5''), 135.2 (C-1', C-1''), 171.5 (C-2, C-6); HRMS (ESI–) calcld for C₁₃H₁₁N₂O₂ 265.0977 (M–H⁻) found 265.0982. (3S,5R)-3f: white powder; mp 172–174 °C; TLC (PE/AcOEt 3:1): Rf = 0.10; [α]D = 0 (c 0.733, CHCl₃); IR (KBr): 698, 737, 1219, 1263, 1454, 1709, 3034, 3065, 3103, 3223, 3137; ¹H NMR (CDCl₃, 500 MHz): δ 2.22 (bs, 1H, NH), 4.75 (s, 2H, H-3, H-5), 7.35–7.44 (m, 6H, H-Ar), 7.45–7.49 (m, 4H, H-Ar), 8.08 (bs, 1H, CONHCO); ¹³C NMR (CDCl₃, 125 MHz): δ 65.1 (C-3, C-5), 128.7 (C-2', C-6', C-2'', C-6''), 128.8 (C-3', C-5', C-3'', C-5''), 129.0 (C-4', C-4''), 135.9 (C-1', C-1''), 171.2 (C-2, C-6); HRMS (ESI–) calcld for C₁₆H₁₆N₂O₂ 265.0977 (M–H⁻) found 265.0976.

(+-)-4-Benzyl-3-phenylpiperazine-2,6-dione rac-3f

From rac-2f (0.32 g, 1.03 mmol) and NaOH (0.04 g, 1 equiv.); FC (gradient: PE/EtOAc 3:1–1:1); yield 0.28 g (98%); white powder; mp 156–169 °C; TLC (PE/AcOEt 3:1): Rf = 0.22; IR (KBr): 698, 744, 1246, 1454, 1699, 2814, 2852, 2924, 3030, 3209; ¹H NMR (CDCl₃, 500 MHz): δ 3.30 (d, 3J₂ = 17.5, 1H, PhCH₂), 3.57 (d, 3J₁ = 17.5, 1H, PhCH₂), 3.63 (d, 3J₂ = 13.5, 1H, H-3), 3.83 (d, 3J₁ = 13.5, 1H, H-3'), 4.50 (s, 1H, H-5'), 7.23–7.39 (m, 6H, H-Ar), 7.41 (m, 4H, H-Ar), 8.24 (bs, 1H, CONHCO); ¹³C NMR (CDCl₃, 125 MHz): δ 51.3 (PhCH₂), 58.7 (C-3), 67.1 (C-5), 128.1, 128.8 (C-4', C-4''), 128.1, 128.8 (C-2', C-2'', C-6', C-6''), 128.9, 129.0 (C-3', C-5', C-3'', C-5''), 134.0, 136.2 (C-1', C-1''), 170.1 (C-6), 171.0 (C-2); HRMS (ESI–) calcld for C₁₇H₁₆N₂O₂ 279.1133 (M–H⁻) found 279.1126.

Pharmacological evaluation

The compounds obtained have been submitted for in vivo evaluation in the ASP of NINDS, Bethesda, USA (White et al., 2002). The experiments were performed in male albino Carworth Farms No. 1 mice (weighing 18–25 g). The animals had free access to feed and water except during the actual testing period. Housing, handling, and feeding were all in accordance with recommendations contained in the “Guide for the Care and Use of Laboratory Animals.” The test compounds were dissolved or suspended in 0.5 % (v/v) aqueous solution of methylcellulose.

The MES test

In the MES test, an electrical stimulus of 0.2 s in duration (50 mA in mice) was delivered via corneal electrodes primed with an electrolyte solution containing an anesthetic agent. Mice were tested at least two different time points (15 min, 30 min, 1 h or 4 h) following intraperitoneal administration of 30, 100, and 300 mg/kg of test compound. Abolition of the hindlimb tonic extensor component indicated the test compound’s ability to inhibit MES-induced seizure spread (White et al., 2002).

The scMET seizure test

The test utilized a dose of metrazole (pentylentetrazole, 85 mg/kg in mice). This produced clonic seizures lasting for a period of at least 5 s in 97% (CD₉₇) of animals tested. At the anticipated time of testing, the convulsant was administered subcutaneously. The test compound was administered intraperitoneally in mice and the animals were observed over a 30 min period. Mice were tested at least two different time points (15 min, 30 min, 1 h or 4 h) following intraperitoneal administration of 30, 100, and 300 mg/kg of test compound. The absence of clonic spasms indicated a compound’s ability to abolish the effect of pentylentetrazol on seizure threshold (White et al., 2002).
The acute neurological impairment (TOX)

Neurological toxicity induced by a compound was detected in mice or rats using the standardized rotorod test (Dunham and Miya, 1957). Mice were tested at a minimum of two different time points (15 min, 30 min, 1 h or 4 h) following intraperitoneal administration of 100 mg/kg of test compound. Rats were tested at time intervals between 0.25 and 4 h following an oral or intraperitoneal dose of 30 mg/kg. Neurological impairment was demonstrated by the inability of animals to maintain equilibrium on a 6 rpm rotation rod for a given time.

The minimal clonic seizure test (6 Hz)

The 6 Hz screen was carried out according to the protocol originally described by Brown et al. (1953) and more recently by Barton et al. (2001) and Kaminski et al. (2004). It is an alternative electroshock paradigm that uses low-frequency (6 Hz), long-duration (3 s) electrical stimulation. Mice were tested at time intervals between 0.25 and 4 h following intraperitoneal doses of 100 mg/kg of test compound. Concomitant stimulation (0.2 ms-duration monopolar rectangular pulses at 6-Hz for 3 s) was delivered by a constant-current device. During the stimulation, mice were manually restrained and released into the observation cage immediately after the current application. The seizures manifested in “stunned” posture associated with rearing, forelimb, automatic movements and clonus, twitching of the vibrissae and Straub-tail. The duration of the seizure activity ranged from 60 to 120 s in untreated animals. At the end of the seizure, animals resumed their normal exploratory behavior. The experimental endpoint was protection against the seizure. The animal was considered to be protected if it resumed its normal exploratory behavior within 10 s from the stimulation (Kaminski et al., 2004).

Acknowledgments We would like to thank the Anticonvulsant Screening Program (National Institute of Neurological Disorders and Stroke, NINDS Rockville, MD, USA) staff for providing the pharmacological data. We would also like to thank Carolyn Foster for her assistance in preparation of the manuscript. Financial support was provided by the Polish Ministry of Science and Higher Education (Grant No. N N405 623138).

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

Banerjee PS, Sharma PK (2012) New antiepileptic agents: structure–activity relationships. Med Chem Res 21:1491–1508

Barton ME, Klein BD, Wolf HH, White HS (2001) Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsia Res 47:217–227

Bialer M, White HS (2010) Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov 9:68–82

Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS (2013) Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). Epilepsia Res 103:2–30

Brodie MJ (2001) Do we need any more antiepileptic drugs? Epilepsia Res 45:3–6

Brown WC, Schifferman DO, Swinyard EA, Goodman LS (1953) Comparative assay of an antiepileptic drugs by psychomotor seizure test and minimal electroshock threshold test. J Pharmacol Exp Ther 107:273–283

Dawidowski M, Herold F, Chodkowski A, Kleps J, Szulczczyk P, Wilczek M (2011) Synthesis and anticonvulsant activity of novel 2,6-diketopiperazine derivatives. Part 1: perhydropyrido[1,2-α]pyrazines. Eur J Med Chem 46:4859–4869

Dawidowski M, Herold F, Chodkowski A, Kleps J (2012a) Synthesis and anticonvulsant activity of novel 2,6-diketopiperazine derivatives. Part 2: perhydropyrido[1,2-α]pyrazines. Eur J Med Chem 48:347–353

Dawidowski M, Herold F, Turko J, Wilczek M, Chodkowski A, Gomolka A, Kleps J (2012b) Synthesis of bicyclic 2,6-diketopiperazines via a three-step sequence involving an Ugi five-center, four-component reaction. Tetrahedron 68:8222–8230

Demharter A, Hörler W, Eberhardt H, Ugi I (1996) Synthesis of chiral 1,1′-iminodicarboxylic acid derivatives from α-amino acids, aldehyde, isocyanides, and alcohols by the diastereoselective five-center-four-component reaction. Angew Chem Int Ed 35:173–175

Dunham MS, Miya TA (1957) A note on a simple apparatus for detecting neurological deficit in rats and mice. J Am Pharm Assoc Sci Ed 46:208–209

Kaminski RF, Livingood MR, Rogawski MA (2004) Allopropagationone analogs that positively modulate GABA receptors protect against partial seizures induced by 6-Hz electrical stimulation in mice. Epilepsia 45:864–867

Kwan P, Brodie MJ (2000) Early identification of refractory epilepsy. N Engl J Med 342:314–319

Löschner W, Schmidt D (1994) Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation? Epilepsy Res 17:95–134

Malawska B (2005) New anticonvulsant agents. Curr Top Med Chem 5:69–85

Mishra R, Ganguly S (2012) Imidazole as an anti-epileptic: an overview. Epilepsia Res 21:3929–3939

Perucca E, French J, Bialer M (2007) Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol 6:793–804

Rogawski MA (2006) Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res 69:273–294

Smith M, Wilcox KS, White HS (2007) Discovery of antiepileptic drugs. Neurotherapeutics 4:12–17

White HS, Woodhead JH, Wilcox KS, Stables JP, Kuperberg HJ, Wolf HH (2002) General principles: discovery and preclinical development of antiepileptic drugs. In: Levy RH, Mattison RH, Meldrum BS, Perucca E (eds) Antiepileptic drugs, 5th edn. Lippincott Williams and Wilkins Publishers, New York, pp 6–48